Our Funding
Overview
Our funders
SMA Europe receives funding from its member organisations, in the form of an annual membership fee and of voluntary donations towards our Call for Research Proposals. In addition, we receive funding from other non-profit organisations and from health sector corporates.
Our funders respect SMA Europe’s mission, strategy, independence, and integrity.
SMA Europe has adopted a code of practice for relationships with the pharmaceutical industry and all our funding partnerships are established with shared interest, transparency, trust, and mutual benefit.
For more information, please contact us at secretariat@sma-europe.eu.
Breakdown
Financial information 2024
In 2024 SMA Europe’s revenue was 1,313,961.88 €, while the organisation’s total expenses amounted to 1,049,766.08 €.
Valued support
Acknowledgements
SMA Europe appreciates the donations received from all its funders. Ensuring a sustained variety of funding is key to minimise potential conflicts of interest and to ensure the sustainability of the organisation.
SMA Europe would like to thank the following partners for their highly valued support in 2024:
SMA Europe’s Member Organisations (in alphabetical order of countries)
- SMA Austria
- SMA Belgium
- Muscular Dystrophy Association Cyprus (MDA Cyprus)
- SMÁci, z. s. (Czech Republic)
- Muskelsvindfonden (Denmark)
- SMA Finland
- AFM-Téléthon (France)
- Deutsche Gesellschaft für Muskelkranke (DGM)/ Initiative SMA (Germany)
- Muscular Dystrophy Association Hellas (MDA) (Greece)
- SMA Foundation (Hungary)
- FSMA (Iceland)
- SMA Ireland
- Families of SMA Israel
- Famiglie SMA (Italy)
- Prinses Beatrix Spierfonds (Netherlands)
- Vereniging Spierziekten Nederland (Netherlands)
- Stop SMA North Macedonia
- Fundacja SMA (Poland)
- Associação Portuguesa de Doentes Neuromusculares (APN) (Portugal)
- Asociația SMACare (Romania)
- SMA Family Foundation Russia
- SMA Serbia
- SMA Slovakia
- FundAME (Spain)
- Nätverket för spinal muskelatrofi (NSMA) (Sweden)
- SMA Schweiz (Switzerland)
- SMA Benimle Yürü (Turkey)
- Turkey SMA Foundation
- SMA UK
- Children with SMA (CSMA) (Ukraine)
Partner Organisations
- Cure SMA (US)
- Cure SMA India
- AMDA
- EMA (European Medicines Agency)
- ENMC
- EURO-NMD
- Eurordis
- SMA Foundation (US)
- Treat-NMD
Industry Partners
- Biogen
- Biohaven
- Bio-Techne (Asuragen)
- F. Hoffmann-La Roche AG
- ImmunoIVD
- LaCAR MDX Technologies
- NMD Pharma
- Novartis
- Revvity
- Scholar Rock
Other Partners
- 161 Consulting Ltd - Michelle Levene
- Alliance of Regenerative Medicines (ARM)
- Artistica Music & Show SCpA - Federico Malandrino
- Bansbach GmbH
- Gardner Puzelli Media
- Hernández, Elena Díez
- Karakaya, Seda
- Kephren Publishing
- Krishna Consultancy – Ankita Batla
- MC Copigrafia
- MediCongress Services N.V.
- Newus
- Patvocates – Anne-Pierre Pickaert
- Piagmo Teknoloji Limited
- Pfeuffer, Armin Dipl.-Kfm
- Rare Revolution Magazine
- Rarity Life Magazine
- Rastogi, Akshat
- Saupe, Laura
- Smart soc. Coop Impresa Sociale - Francesco Dragone
- Tóth, Tímea
SAB
SMA Europe Scientific Advisory Board
A special acknowledgement and ‘Thank you’ to our Scientific Advisory Board (SAB). Our SAB is composed of an international group of neuroscientists and neurologists with particular expertise in spinal muscular atrophy (SMA) research, and advises us on our scientific congresses, clinical trials initiatives and on the selection and appraisal of the research grants we award.
Our SAB members are:
- Tom Gillingwater, PhD (Chair, UK)
- Stefania Corti, MD, PhD (vice-Chair, Italy)
- Melissa Bowerman, PhD (UK)
- Claudio Bruno, MD, PhD (Italy)
- Peter Claus, PhD (Germany)
- Richard Finkel, MD (USA)
- Ewout Groen, PhD (The Netherlands)
- Cécile Martinat, PhD (France)
- Christian Simon, PhD (Germany)
- Charlotte Sumner, BA, MD (USA)
- Ludo Van der Pol, MD, PhD (The Netherlands)
- Ulrika Kreicbergs, RN, PhD (Sweden)
Related resources